Raider storms Havas board, shadowing Euro RSCG Life

Share this article:
French corporate raider Vincent Bollore has captured four seats on the board of Havas, throwing a shadow over the future of the holding company, which includes one of the biggest names in medical advertising, Euro RSCG Life.

Bollore won 59.31 percent of shareholder votes, allowing him to seat himself and three deputies on the company's 18-person board. Bollore, who holds 20 percent of the company's shares, said recently that he would remain a minority shareholder and that he is in it for the long haul. The vote nonetheless comes as a blow to chairman and chief executive Alain de Pouzilhac, who has sworn to maintain Havas' independence and called Bollore's encroachment a "creeping takeover."

Bollore's advance stirred speculation of a breakup of the company, which has slipped behind rivals Omnicom, WPP, Interpublic and Publicis as it was shut out of the recent binge of consolidation in the advertising world. Most recently, Havas lost out to WPP in its bid for Grey Global Group, which was complicated by Bollore's opposition to an acquisition. Bollore has also criticized foreign investments that the French company has made.

In addition to Euro RSCG Life, thought to be the world's fourth-largest medical advertising firm, Havas, the world's fifth-largest marketing company, includes two mainline advertising networks – Euro RSCG and Arnold Partners – along with Media Planning Group, a media buying and planning network.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.